J 2024

Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score

WENZL, Florian A, Peizhi WANG, Mattia ARRIGO, Jiří PAŘENICA, Donald J L JONES et. al.

Základní údaje

Originální název

Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score

Autoři

WENZL, Florian A, Peizhi WANG, Mattia ARRIGO, Jiří PAŘENICA, Donald J L JONES, Francesco BRUNO, Daniel TARNWSKI, Oliver HARTMANN, Luboš BOUČEK, Fabian LANG, Slayman OBEID, Andreas SCHOBER, Simon KRALER, Alexander AKHMEDOV, Florian KAHLES, Alexander SCHOBER, Kok Weng OW, Stefano MINISTRINI, Giovanni G CAMICI, Andreas BERGMANN, Luca LIBERALE, Jiri JARKOVSKY, Victor SCHWEIGER, Jatinderpal K SANDHU, Arnold von ECKARDSTEIN, Christian TEMPLIN, Olivier MULLER, Tomáš ONDRÚŠ, Olic JANET-JACQUELINE, Marco ROFFI, Lorenz RÄBER, Thong H CAO, Carsten G JUNGBAUER, Leong L NG, Alexandre MEBAZAA a Thomas F LÜSCHER

Vydání

European Heart Journal, OXFORD, OXFORD UNIV PRESS, 2024, 0195-668X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 39.300 v roce 2022

Organizační jednotka

Lékařská fakulta

UT WoS

001318498800001

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 11. 2024 09:49, Mgr. Tereza Miškechová

Anotace

V originále

Background and Aims Circulating proenkephalin (PENK) is a stable endogenous polypeptide with fast response to glomerular dysfunction and tubular damage. This study examined the predictive value of PENK for renal outcomes and mortality in patients with acute coronary syndromes (ACS). Methods Proenkephalin was measured in plasma in a prospective multicentre ACS cohort from Switzerland (n=4787) and in validation cohorts from the UK (n=1141), Czechia (n=927), and Germany (n=220). A biomarker-enhanced risk score (KID-ACS score) for simultaneous prediction of in-hospital acute kidney injury (AKI) and 30-day mortality was derived and externally validated. Results On multivariable adjustment for established risk factors, circulating PENK remained associated with in-hospital AKI (per log2 increase: adjusted odds ratio [OR] 1.53, 95% confidence interval [CI] 1.13–2.09, P=0.007) and 30-day mortality (adjusted hazard ratio [HR] 2.73, 95% CI 1.85–4.02, P<0.001). The KID-ACS score integrates PENK and showed an area under the receiver operating characteristic curve (AUC) of 0.72 (95% CI 0.68–0.76) for in-hospital AKI, and of 0.91 (95% CI 0.87–0.95) for 30-day mortality in the derivation cohort. Upon external validation, KID-ACS achieved similarly high performance for in-hospital AKI (Zurich: AUC 0.73, 95% CI 0.70–0.77; Czechia: AUC 0.75, 95% CI 0.68–0.81; Germany: AUC 0.71, 95% CI 0.55–0.87) and 30-day mortality (UK: AUC 0.87, 95% CI 0.83–0.91; Czechia: AUC 0.91, 95% CI 0.87–0.94; Germany: AUC 0.96, 95% CI 0.92–1.00) outperforming the CA-AKI score and the GRACE 2.0 score, respectively. Conclusions Circulating PENK offers incremental value for predicting in-hospital AKI and mortality in ACS. The simple 6-item KID-ACS risk score integrates PENK and provides a novel tool for simultaneous assessment of renal and mortality risk in patients with ACS.